Table 3.

Summary of recommended best practices for data annotation.

• Clinical minimal annotations per 2016 REiNS Biomarker guidelines

∘ Standardized vocabulary using the Observational Medical Outcomes Partnership Oncology Module supplemented by 2016 REiNS Biomarker guideline terms

• Sample annotation should describe samples of interest as well as matched datapoints/studies

∘ Time from sample collection to sample processing/storage

∘ Minimal annotation of paired tissue should:

■ Detail timing relative to the candidate biomarker collection

■ Document timing relative to administration of last dose of therapeutic agent (if applicable)

■ Document timing from tissue collection to processing/storage

■ Address all criteria of consensus histologic or genomic guidelines

∘ Minimal annotation of paired imaging should:

■ Detail timing relative to the candidate biomarker collection

■ Detail imaging modality and anatomic locations

■ Include ADC if DWI performed

■ Include SUV if PET performed

■ Include sum of the longest diameter and, if available, volumetrics

■ Include RECIST category, if relevant

• NF1/SWN experimental data should be annotated per the NF OSI metadata dictionary ontology and data structure.

• We recommend harmonization of existing NF1/SWN data through funding and maintenance of extraction, transformation and loading processes with disease-specific terms and dictionaries on a central NF1/SWN data repository.

REiNS: Response Evaluation in Neurofibromatosis and Schwannomatosis; NF1: neurofibromatosis 1; SWN: schwannomatosis; ADC: apparent diffusion coefficient; SUV: standardized uptake value; DWI: diffusion weighted imaging; OSI: open science inititiave.